Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Clover Biopharmaceuticals IPO: Forecasts and Valuation

Clover Biopharmaceuticals IPO: Thoughts on First Day Trading

Paytm IPO: More Expensive than Global Payment Giants and SOTP Suggests More Than 40% Discount

Baycurrent Consulting: Strong Fundamentals; Up Almost 200% and Further Upside Likely

Beijing Airdoc IPO: First Mover in Retina-Based Early Detection and Diagnosis

Abbisko IPO: Some Products Show Good Potential but Too Early to Assess Their Success

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Clover Biopharmaceuticals / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/clover-biopharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:33029:1" rel="noopener">Clover Biopharmaceuticals (CBL HK)</a> is a global clinical-stage biotechnology company that is focused on the research, development and the commercialisation (if approved) of novel vaccines and biologic therapeutic candidates. The company’s business model focuses on in-house research and development of novel vaccines and biologic therapeutic products. Clover’s most advanced drug asset is a Covid-19 vaccine candidate, SCB-2019 and the company expects to submit applications for conditional regulatory approval to the EMA, the NMPA and the WHO in 4Q2021 and expects to receive approvals between 4Q2021 to mid-2022.</p><p>Clover has filed for an IPO on the Hong Kong Stock Exchange and in this insight, we examine the company’s product candidates, competition and the outlook for the company.</p>

Clover Biopharmaceuticals (CBL HK) is a global clinical-stage biotechnology company that is focused on the research, development and the commercialisation (if approved) of novel vaccines and biologic therapeutic candidates. The company’s business model focuses on in-house research and development of novel vaccines and biologic therapeutic products. Clover’s most advanced drug asset is a Covid-19 vaccine candidate, SCB-2019 and the company expects to submit applications for conditional regulatory approval to the EMA, the NMPA and the WHO in 4Q2021 and expects to receive approvals between 4Q2021 to mid-2022.Clover has filed for an IPO on the Hong Kong Stock Exchange and in this insight, we examine the company’s product candidates, competition and the outlook for the company.

Clover Biopharmaceutical IPO: Covid-19 Vaccine Candidate Shows Strong Potential